Skip to Content

Myriad Genetics Inc MYGN Stock Quote

| Rating as of


Last close prices updated as of Feb 03, 2023, 4:00 PM EST | USD | BATS BZX Real-Time Price
  • Last Close 19.96
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Investment Style Small Value
  • Day Range 19.81  –  20.89
  • Year Range 13.92  –  28.18
  • Market Cap 1.6174 Bil
  • Volume / Avg 603,039.0 /  764,852.9
  • Price / Sales 2.42
  • Price / Book 1.76
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis MYGN

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Myriad Genetics Invests in Growth Opportunities; Shares Appear Slightly Overvalued

Karen Andersen Sector Strategist

Business Strategy and Outlook

| Karen Andersen |

Myriad Genetics started out as the monopoly in hereditary breast cancer diagnostics. Its oldest test was BRACAnalysis, a predictive test for mutations tied to an increased risk of hereditary breast or ovarian cancer. It had exclusive testing rights with patents on isolated BRCA1 and BRCA2 genes until a 2013 Supreme Court decision ruled that isolated DNA cannot be patented, stripping away the company's intellectual property in its hereditary cancer suite. Since then, Myriad has tried to pivot to a more diverse diagnostic portfolio that builds on its expertise in hereditary diagnostics while moving into new markets, including hereditary predisposition for a range of cancers, noninvasive prenatal testing, and efficacy of drugs for depression.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics MYGN

Company Profile MYGN

Business Description

Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual’s risk of developing a disease. The firm produces MyRisk, a 35-gene panel with the capability to identify the elevated risk of developing eight types of cancer. Other diagnostic products include BRACAnalysisCDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; Prequel, with is a noninvasive prenatal test; and Prolaris, which identifies prostate cancer patients that can pursue active surveillance. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

320 Wakara Way
Salt Lake City, UT, 84108
Industry Diagnostics & Research
Employees 2,400

Related Articles MYGN

FAQs for Myriad Genetics Inc Stock

No. MYGN does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

MYGN’s market cap is 1.62 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

MYGN’s stock style is Small Value.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

MYGN’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare MYGN’s historical performance against its industry peers and the overall market.